Cxcr5 Modified Egfr Chimeric Antigen Receptor Autologous T Cells
Non-Small Cell Lung Carcinoma
Sun Yat-sen UniversityCell therapyPhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 65/ 100
Competitive context
1205 Active assets in the Non-Small Cell Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BBB |
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
Icotinib The First Affiliated Hospital of Guangzhou Medical University | Phase 4 | BBB |
Veliparib AbbVie | Phase 3 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →